top question manag team
life scienc tool diagnost sector review
ahead upcom investor confer manag meet compil list
relev question topic discuss respect manag team across
divers coverag univers life scienc tool diagnost compani emphasi
follow sub-sector anim health contract servic organ clinic laboratori
dental life scienc among other pleas reach team copi latest
model request prepar meet
life scienc tool diagnost bankshot lst ep report qtd
anim track ep driver anim
clinic laboratori updat diagnos state test part
dental updat survey say dental demand unsurprisingli deterior
chwi virtual rode manag
life scienc tool diagnost expert call dissect state dx test
state cro industri trial enrol delay normal cancel rate
cro download catch focu
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
tabl content
labcorp america lh
compani data credit suiss factset million except per share data
base factset consensu estim se estim
priceupsid weekavg dailyrevenu cy average cy average cy ev/ebitda cy targetdownsidepricecap high lowvol zoeti anim laboratori inc anim research organizationsiqvia inc river scienc diagnosticsthermo hold charl martineau univers toronto
experienc million top-line headwind
million headwind outsid china help us understand geographi
impact impact began across region
note china recov market rel januari level
updat progress see pent demand
provid updat trend see north america to-dat
extent practic shutter begin see practic reopen
help us think geographi recoveri stage pace
recoveri geographi compar china
recent maintain long term outlook ex coronaviru help
us get comfort lt model light underli growth retreat lower
end guid past year conservative/achiev lt target
key underli driver
think balanc follow declin
discuss factor contribut on-going asp pressur fx vs mix shift
updat think asp trend longer term
speak new consum orient market activ strategi
tv vs on-line vs print teen vs adult exactli campaign start
reduc activ light current environ covid
term doctor-ori effort promot leverag
directli price concess bundl co-market
broader macro perspect speak sensit across busi
potenti volatil macro environ
normal environ think margin benefit ramp
new china manufactur facil variou treatment plan facil longer term
speak relationship aspen dental heartland dental
dso strategi would character discuss dso profit dynam
give us updat third-parti financ initi econom behind
offer key growth driver longer term traction
capit deploy prioriti philosophi type asset might make sens
larg deal would compani consid
thought move non-gaap basi exclud stock-bas compens
one-tim item
speak evolut doctor-direct competit landscap
sort feedback
hear marketplac competit across ortho vs gp market
straumman clearcorrect product compar invisalign
think potenti impact launch market intern price
import patent limit competitor particip market vs
extent barrier entri driven deep market penetr market
think threat competit direct consum clear align
busi quantifi overlap
non-compet end sdc expect open own invisalign
store similar previou strategi
sdc recent announc intent sell clear align doctor-direct
channel initi thought around feasibl strategi potenti impact
percent teen case mandibular advanc repres time/market
opportun extend penetr product contribut growth
also estim teen case shipment invisalign first
think invisalign first growth go forward
brazil/latam speak traction see brazil think
market opportun
traction see smile concierg servic launch
speak opportun retail concept walgreen
rate would expect grow number new doctor would
estim current penetr potenti doctor us vs region
ad new doctor long typic take see meaning case volum
ramp similar averag level product rule appli
doctor prescrib case
speak doctor-l invisalign experi locat mani locat
current econom work traction
updat develop pipelin hole still look fill
palat expand focus develop product ortho
think spend come quarter longer term
provid updat itero busi extent see
practition defer capit expenditur to-dat light covid expect
growth trend longer term
recent receiv approv itero element us
acknowledg covid may drive impact speak feedback
gotten to-dat product
timing/magnitude/feedback associ launch new itero cari screen
withdrew guidanc note your see declin across
dental market global extrapol growth remaind quarter
begin see pocket recoveri
specif dental practic traffic trend end-us demand us base
observ convers distributor trend
recent think weve alreadi pass trough demand
outlin dynam across europ broader intern market
particular market experienc recov demand
think apac vs europ
remind us variou product group consum implant ortho
equip perform recess
still confid underli long term target impli bp margin
expans top-line growth walk us
equip experienc recent robust growth innov lap
destock dynam would character underli demand trend
equip think cadenc growth particularli light
provid color one ds promot program launch octob
recent program updat exactli work feedback thu far
seen pullback interest willing purchas primescan/primemil
demand trend lt growth rate gener vs specialti consum
relationship penetr dso account target sale initi
opportun third-parti manufactur partner dtc clear
align compani could impact relationship dental commun
follow million destock step taken gain better
visibl distribut channel
supplier relationship progress updat relationship
salesforc effici initi ramp us expect increas direct
distribut effort speak potenti attract directli
distribut dso
primescan differ omnicam offer product
receiv thu far pushback price open architectur traction vs full chairsid
view new open-architectur approach help address previou key barrier
omnicam broader cad/cam adopt cad/cam penetr stand
today go longer term
primescan anticip greater adopt new user upgrad
upgrad program perform to-dat upgrad program compar
previou program omnicam term time attract offer
recent launch primemil new mill offer chicago midwint
meet februari primemil compar legaci cerec mill offer
compar recent launch competit mill
initi feedback primemil order track rel initi intern
expect pushback price
spoke develop comprehens imag portfolio
speak hole look fill area invest
speak recent launch implant system astra
product fit within broader implant portfolio differenti product
thought implant strategi broadli market share
updat discuss align technolog obtain interoper primescan
invisalign would character upsid interoper
thought recent launch suresmil clear align product
differenti offer market
view market opportun clear align space given
competitor also recent enter space well one domin player help us
understand model opportun tam
target million net cost save think
key compon annual cadenc save initi
acceler cost initi light
speak increment cost mitig initi implement due
abil ramp headwind
meaning extend longer expect
mention redirect spend area product categori
view compel could reinvigor growth
speak initi progress youv made thu far salesforc
execut effort roll-out new sale structur progress us
help us think roll-out geographi time
success drive better effici measur
provid updat portfolio trim effort
much go current sku count sku ration expect
state capit deploy prioriti level leverag
comfort stretch balanc sheet right opportun
thought share repurchas current environ
amazon sort shift either direct third-parti distribut provid
late thought whether on-line retail may provid viabl altern tradit
distributor consum side busi
light withdrew guidanc earli april help us think
youv seen dental demand trend global end
first month
think impact geograph perspect
north america europ row begin see sign strength certain
adjust new stand-alone public compani compar
histor oper umbrella
speak longer term revenu growth algorithm volum vs price equip
 consum vs specialti expect improv organ revenu growth
essenti flat today lsd msd longer term
youv comment consolid effort past sever year
highlight step taken drive effect innov
translat new product launch
speak dealer-partn relationship commit util
tradit distribut compar direct sale effort expect sale
convent distribut sale evolv time
point destock dynam headwind core growth
extent visibl channel stock level step
taken improv channel visibl
dental servic organ dso strategi also help us think
margin dynam relationship
think impact equip vs consum
product group trend qtd
remind us segment perform time-frame consum
would character underli demand consum north america
equip trend north america sell-out trend
tradit equip consum segment weak organ basi
last year growth segment go next five year
normal environ strategi acceler growth
intraor imag becom increas focu across dental market area
notic absent speak new two-prong strategi
recent/upcom kavo launch detail product market
posit capabl price devic control dtx integr
began take order kavo earli decemb recept
thu far prior covid potenti contribut growth
thought chairsid cad/cam offer expect enter
dtx studio also note key innov area speak
softwar compar exist competit offer dtx enhanc overal
intraor imag key area focu innov perspect
across equip consum categori
think impact specialti ortho
implant busi trend qtd
remind us segment perform time-frame implant vs
implant market share today across premium valu market
speak histor market share shift experienc expect
share market go time
nobel biocar declin surpris dynam help us better understand
driver transform effort valu implant reorgan premium
initi begin think impact throughout
histor premium valu implant brand compet
implant strategi chang past year brand
perform sinc strategi shift nobel biocar implant direct logon alphabio
recent announc implant system offer differenti rel
alreadi market price strategi feedback to-dat
covid impact european launch think
adopt cycl type product normal environ lt opportun
rational recent acquisit matricel biomateri manufactur
augment market posit
spark clear align broader strategi spark perform
market fulli launch product australia feedback
speak spark launch strategi relat us expect
fulli launch global price cadenc anticip million contribut
spark throughout target still intact given covid
could launch spark impact growth trajectori convent bracket
 wire offer lt success coexist combin offer
discuss envista busi system philosophi provid
exampl driven enhanc revenu growth cost save
extent target million cost save fall bottom
line vs reinvest cadenc synergi
think longer term margin expans opportun
think oper margin go time
term type compani offer look bolt-on vs new
thought around implement dividend lt
call note run-rat global dental sale
provid updat see quarter-to-d north america
along demand curv believ demand begin trough
alreadi trough seen sign recoveri china pace
recoveri certain geographi to-dat
geographi see meaning better trend rel
countri germani countri perform better
practic slowli begin reopen north america think
dental market recoveri long take market near level
speak expect trajectori consum equip global
dental market recov expect pace recoveri differ
consum equip
normal environ much dental consum growth attribut
think na consum growth longer term
specialti fell intern growth basi vs help us understand
impact covid recessionari environ certain specialti categori
speak market posit across specialti categori expect
differ categori grow go forward level invest ortho vs implant
margin expans opportun next year
speak dso strategi progress thought recent
contract loss pacif dental servic pd upcom re-contract
throughout long contract typic
speak one earli result ventur far demand
gener strategi expand adopt across practic
describ relationship differ across dso henri
schein one fit relationship
detail/provid background dso formulari manag effort
servic provid regard anticip abl
command price
relationship distribut
seen evid greater direct sale initi manufactur
potenti implic xray one ds market program rebat flow
 perspect
think emerg market strategi past acquisit china
distributor thailand growth opportun brazil
amazon thought on-line retail may provid viabl altern tradit
distributor consum stanc issu amazon market share
initi thought xray new cerec primescan/primemil nvst new
kavo trio launch planmeca new printer new ivoclar
remind us strategi relat proprietari product brand area
interest invest product better posit market
speak reveal clear align system price comprehens
packag seem premium industri incumb
feedback to-dat price well product broadli
reveal compar slx system product differenti
product current market plan posit product traction
strateg rational enter clear align market alreadi
clear domin player well variou product launch past year
opportun servic third-parti manufactur partner dtc clear align
compani could repres meaning growth opportun near/mid-term
youv note lack softwar penetr germani prevent bring
current offer germani best pathway gain foothold
speak broader sale trend chairsid vs stand-alone digit impress
unpack medic perform across north america
extent significantli increas person protect equip order drive growth
call note run-rat medic sale
provid updat market to-dat driver declin trend
extent increas sale ppe off-set core medic declin
opportun one medic
margin differ medic dental give us sens
product mix medic highest margin product
driver rel faster growth medic despit low volum environ
updat liquid posit think cash flow end
quit bit cash balanc sheet draw debt
comfort current posit leverag liquid standpoint
type deal interest pursu longer term medic vs dental bolt-
vs transform addit capabl geographi
speak drive growth technolog value-
ad servic segment think growth trajectori nt
youv mention push sell higher margin privat label product talk
associ initi percentag current sale
speak dental market perform quarter-to-d
dental trend track end februari consum vs equip
extent seen impact past two month
remind us dental consum equip trend
recess pace recoveri thereaft
youv previous spoken balanc necessari busi invest margin
stabil provid insight plan
invest plan priorit
talk sale forc initi develop
privat label recent note key growth driver margin benefit
speak privat label strategi evolv past year big
privat label sale today percentag sale go time
interest organ build potenti acquir ancillari busi
recent implement erp system enhanc e-commerc effort
larg public competitor state total sale e-
commerc significantli higher consum rel exposur
think current capit deploy prioriti de-lever share
opportun better penetr dso dso strategi would
character current price environ
recent displac henri schein primari distributor across pacif dental
servic broader book busi expans previou relationship view
drove contract win speak econom contract
relat pd contract win note call repres
million quarter help us think fy contribut contract
extent increment revenu fall consum vs equip
heartland dental relationship gone thu far sale custom
line expect expect see pickup equip demand
custom expand dental equip offer
would character growth differenti tradit dental practic
dso prior pandem pro con
work dso abl win addit busi front late
util rel new promot program one ds speak
potenti implic program
quantifi consum purchas associ practic
purchas cerec primescan unit sort shift seen block
market sinc chang sirona relationship
comment recent aggress price across imag platform
equip financ dental help us think flow
 think go forward
amazon chatter whether on-line retail may provid viabl
altern tradit distributor consum side busi
stanc issu envis amazon meaning competitor longer
speak anim health market perform quarter-to-d
anim health trend track end februari livestock vs
companion anim extent seen impact
given recent closur meat process plant well shift demand shift
purchas protein retail set fulli offset restaur consumptioncan
provid updat swine market beef/dairi market overal exposur
elanco recent announc implement new hybrid approach distribut
util distributor primarili logist vs demand gener expect
relationship shift impact vet busi next year exposur elanco
expect anim health pharmaceut compani follow suit begin
help us think underli factor affect vet oper margin
expans think oper margin go forward longer term
revenu mix companion vs product anim evolv time
expect go futur mix current stand today
impact recent direct relationship manufactur e-commerce chewi
expect minim averag price map impact tradit distribut effort
across vet market go forward
current relationship vetsourc closest competitor vet first
choic would consid merger transact similar particularli
given exist ownership stake
feedback hear market vetsourc rel compet
offer vet first choic adopt trend
market share vet practic manag softwar market share evolv
past five year adopt cloud-bas navetor practic manag platform
would contempl competit dynam chang launch tripl
combin parasiticid flea/tick/heartworm exposur parasiticid
consid conduct strateg review anim health busi
potenti opportun strateg rational retain busi
meaning chang vendor contract calendar year
switch agenc buy/sel
would character current pipelin across dental anim health
gap offer product and/or geograph perspect size
potenti deal
speak clear align sale trend quarter-to-d seen
sign initi recoveri speak rate reopen store
target call revenu growth annual normal
environ ex-covid also prior expect deceler sole
relat capac restraint servic level also predic dynam
lower demand due litig headlin
updat broader market strategi tv ad vs social media vs print given
new control growth strategi dynam correl
market volum extent scale back market effort
speak trend qtd term websit visit appoint book
convers thereon metric trend vs histor experi
address market percentag potenti custom malocclus
effect treat percentag patient turn away
speak patient demograph mix relat age incom threshold
geographi suburban vs citi vs rural area focu
mani practition suggest clear align offer safe and/or
effect clinic test done demonstr safety/efficaci head-to-
size doctor network current requir join doctor network
current doctor capac compar demand doctor retent network expans
extent smilepay financ improv convers sinc launch
expect metric go time today
close bad debt remain meaning higher averag credit card
strategi implement improv metric forese implement
credit check forese futur
sensit analysi relat smilepay financ macro risk
recept nighttim clear align thu far expect
materi contribut growth
expect see meaning contribut newer in-network provid statu
 /aet speak recent announc partnership
aet treat patient remot orthodont care
extent current facil autom today type technolog
look implement time help us think extent
autom drive gross margin expans time
speak rational behind delay invest texa facil
speak senior manag relev experi commit
up-front cost addit smileshop store breakdown
previous youv note smileshop us util prior
view optim util level long take achiev
level expect new store open us beyond
help us think unit econom differenti cvs/walgreen co-
locat store share retail store wework
cvs/walgreen co-loc store locat perform rel
share retail store wework prior pandem
speak intern smileshop strategi expect open
stand-alone store share retail store co-loc store partner locat
recent announc new strateg relationship offer
line premium oral care product store domest rational
behind manufactur product like tooth brush etc think
growth revenu longer term
lawsuit effect forc close
invisalign experi store also extend non-compet speak
outcom litig longer term implic non-compet expir
weve seen numer new dtc entrant space extent view
new player competit threat
candidco appear closest competitor dtc market walk
sdc model offer differenti rel candidco
rational behind recent announc wholesal clear align dentists/ortho
decis sell impress kit dentists/ortho feedback to-dat
impact perform to-dat intern
pandem potenti chang global expans strategi
rational behind priorit expans us growth focu current
intern geographi vs new market
discuss price strategi new market think
current geographi vs us time
intern market anticip expand next year
factor drive decis expand new market
recent pushback practition around sdc abil practic dentistri
dynam refut call dso corpor structur speak
corpor structur implic
help us understand implic ab california call
radiograph equival bone-level imag
california ab also requir licensur relev doctor inform
disclos patient given practition peer clearli look favor upon sdc
employees/contract could impact doctor network
next step california timelin implement
happen lead point expect address ab
thought british dental associ recent call evid risk remot
regulatori dynam awar
view underli demand trend pet care anim health market pet
primari rational give revenu guidanc expect
revenu ebitda target
speak data scienc suppli chain optim busi
see higher visibility/ predict revenu initi
contribut gross margin
logist side new fulfil center north carolina
pennsylvania progress speak differ tradit
fulfil center new autom fulfil center pa net cost save
expect autom fulfil center move forward
speak lt gross margin trajectori target key initi
contribut achiev target
give color mix shift trend see increas
traction higher-margin hard-good privat label pharmaci product
speak season impact revenu gross margin year
turn profit annual basi
plan intern expans
spoke meaning heighten demand driven covid-induc channel
shift on-line includ increas new custom increas order exist
custom insight qualiti new custom cohort
purchas pattern similar tradit first-tim custom autoship rate new
mention market team prepar tri turn new custom
long-term sticki custom give color tactic plan
call meaning hire ramp meet covid-rel demand
increas headcount employe speak rational
behind hire pure meet covid demand hire efficient/sustain
stockpil dynam commentari mix shift consum custom
stock essenti impact margin
suppli chain disrupt note give color your
experienc fulfil backlog your allevi backlog
impact purchas behavior
see heighten demand pharmaci offer time
veterinarian will work fulfil prescript consid disrupt
busi
speak new data manag platform shape
market effort said market
technolog stack need get look like
updat current market initi drive convers
give updat new app custom engag percent
order origin app
long-term target advertis spend percent sale expect linear
progress fluctuat
mention look partner vet fill prescript via chewi
pharmaci busi give color partnership progress
strategi regard partnership would will someth along
line covetrus/vet first choic share econom veterinarian
earli feedback veterinarian regard new pharmaci offer
long-term target growth margin profil pharmaci mention gross
margin improv bp pharmaci speak drove
whether continu expect kind expans expect
notic abnorm order trend parasiticid enter flea/tick
season consid near launch simparica trio
quantifi over-the-counter busi includ segment
kind invest need make near term pharmaci
competit landscap speak risk amazon enter pet rx space
competit wal-mart pet rx
map price affect consid posit neg
industri fulli lap benefit
mention hope achiev north privat label sale long-term
progress give color core strategi relat privat
highlight frisco call largest privat label brand
continu add brand focu expand presenc current brand
dramat margin profil differ privat label product
recent fda warn grain-fre dog food affect
relationship third parti seller creat meaning opportun switch
custom privat label brand
would character underl demand thu far april/may current covid-
environ extent volum impact think
timeline/pac potenti recoveri
think impact recent decis market product
directli custom ration distribut awar
contempl shift strategi current exposur elan/ bayer
expect manufactur take target distribut approach
current supplier concentr largest supplier
mitig exposur implic recent consolid
speak strateg vision benjamin wolin appoint
perman role ceo updat compani strategi prior focu
new initi highlight recent manag shift
call million stock benefit europ apac relat
expect addit stock dynam go forward
underli driver strength across north america busi past quarter
think distribut revenu growth rel grow contribut
vet first choic platform normal demand environ
expect switch tradit buy/sel relationship agenc transact near
term vice versa meaning intern synergi target term
convert agenc sale platform
speak relationship corpor account see
evolv next sever year comment mars/woof relationship shift
often contract renew chang nva
privat label strategi expect expand privat label portfolio meaning
think privat label penetr go term percentag total
sale econom compar privat label brand name item
third-parti product garner attent product launch
tripl combo repres meaning opportunities/risk
price ration marketplac see competitor includ direct
sale effort manufactur undercut price certain product
would character on-line pharmaci prescript manag demand trend
call growth much driven new custom
enrol vs exist custom much demand expect perman
remain on-line trend normal amidst covid
walk us econom vet first choic platform
receiv vs veterinarian vs manufactur compar vetsourc
platform structur profit dynam vet
speak impact recent effort manufactur establish direct
relationship altern on-line concept chwi
manufactur go direct altern channel constitu chewi theyr
enforc minimum averag price map implic map vfc/price vet
clinic level much benefit recent quarter
think penetr platform number doctor
onboard custom util thereon activ therapi manag same-
add veterinarian platform long take see meaning
contribut ramp typic look like
think potenti opportun telemedicin anim health
give color newli integr telemedicin solut
call focu drive engag vs focus sole new enrol
highlight initi drive util driver same-stor sale growth
vet first choic platform intern speak potenti timelin
expans countri look
updat ebitda growth expect beyond vs dd expect
announc transact key driver potenti risk
speak synergi captur progress to-dat far behind schedul
first year breakdown revenu vs cost synergi
still expect achiev million synergi year three
catch still expect cost vs revenu synergi breakdown
mergers/divestitures/ipo anim health pharmaceut market impact
think margin go overtim
speak amend debt coven net debt stand current
plan debt paydown beyond
give color recent announc million convert prefer
equiti invest clayton dublili rice deal impact liquid
leverag posit particularli light covid dynam
would character current fundament dynam companion anim
market current covid environ thought vet util trend pet
explain flow fx gross margin oper margin line
anticip term fx top-line profit perspect
total exposur product anim unit state abroad
speak see product anim busi relat
contraction/expans cattl herd size feed cost cattl feed relev
variabl light see swine market poultri impact
process facil closur
speak transit servic agreement tsa henri schein
impact servic tsa includ
speak impact recent simparica trio launch potenti market
would character current fundament dynam product anim relat
contraction/expans cattl herd size feed cost cattl feed
relev variabl covid environ think segment
nt lt exposur busi mix evolv time
speak underli demand trend impact companion
anim segment thu far april/may character vet utilization/pet ownership
trend spending/pet think possibl timelin recoveri
speak rational behind decis ration third-parti
distribut relationship gener demand internally/ market directli custom
target distribut strategi covid dynam factor catalyst
chang think strategi shift impact sale
well long-term sort increment invest need make
salesforc accomplish strategi
call million destock relat new strategi addit
million expect destock beyond
think covid-rel dynam food anim speak
impact process facil closur expect normal suppli chain
capac resum shift restaur retail impact busi
segment timelin possibl recoveri
insight consum spend trend current macroeconom environ
think perform companion anim food anim
segment recessionari environ
elabor million competit headwind
current expect rumensin given gener competit custom feedback/
chang assumpt follow recent launch simparica trio zoeti
give color resumpt steril inject product sale
expect micotil tylan dectomax
explain flow fx gross margin oper margin line
much impact result anticip term fx
top-line profit perspect
note would like continu launch three new product per year expect
abl launch three new product
mention launch equival five like launch
end get sens launch look like
legaci aratana product speak traction/contribut nocita entyc
updat timelin entyc cat
near term expect gallipr perform learn
us experi help acceler revenu quickli geographi
traction thu far new launch brazil
opportun atop dermat compet portfolio
ad pipelin develop stand categori jak inhibitor
note introduc medic import antibiot altern pipelin
talk opportun exampl
opportun see monoclon antibodi
flea/tick/heartworm combo product remind us potenti impact new
competitor parasiticid far along competit combin product
new product gener million revenue speak product
drove perform expect new product go back ad basi point
sale growth quarterli basi demand trend normal
credelio cat launch timing/magnitud contribut us timelin
geographies/ label expans plan gallipr credelio
expect collabor novozym cattl nutrit
would product born fall futur protein rumin swine
cost structur initi impact nt longer term
cost-cut goal would character execut date effort
think lt gm profil given mix shift particularli
recent quarter potenti margin improv product mix vs cost taken
breakdown profit segment speci group
plan introduc metric help us track perform effici effort
ration procur renegoti
opportun reduc sku count
speak covid impact underli demand trend differ geographi
tend see market along term recoveri
geographi see largest opportun lt companion anim food
anim geographi deemphas part restructur initi
still expect african swine fever neutral growth quantifi
headwinds/tailwind vs offset geographies/ speci
seen evid repopul china
vfd compar european regul well antibiot regul
market expos product explain regulatori dynam vs
consumer-driven pressur relat antibiot
ractopamin market sell optaflexx paylean experior offset
sale via altern channel increas significantli past two year drove
keep tight watch inventori channel petsmart chwi
highlight altern channel sale key strateg focu move forward
speak relationship channel chwi
evolv strategi grow categori exposur today lt target
speak potenti implic new e-commerc concept vet first
choic vetsourc opportun risk view
updat pend acquisit bayer anyth comment term
divestitur timelin expect trend vs initi announc
time debt paydown gross leverag
dividend expect near-term long-term
type opportun would consid near term longer term
opportun diagnost
would character current veterinari demand trend qtd walk us
clinic traffic volum pattern compar see
think timelin pace recoveri normal trend
recoveri look like geographi china
think perform differ area busi
segment lever well vet traffic
sustain price dynam econom downturn
quantifi overal nt lt opportun associ prevent care
initi tangibl datapoint track progress
much custom base use refer laboratori point care
dual-mod overlap trend metric go time
driver practic volum revenu strength track system
room run term broader demand growth util us
speak rational behind cost mitig effort salari reduct vs
lever could pull
feedback digit cytolog offer launch vmx speak
market size potenti revenu opportun product traction thu far prior
speak initi econom broader roll-out
sdma slide perform impress expect
contribut consum growth ramp time competitor wing
sedivu provid updat placement trend consum
util track traction compar intern expect
catalyst one see meaning step consum util similar
catalyst dx adopt experi thought core chemistri placement trend nt
equip placement trend quantifi upgrad opportun core chemistri
us typic replac cycl
thought rapid assay competit landscap vs first gener product
 much futur invest equip vs novel test vs
system new area test interest explor unmet need
think implic ztss entranc us ref lab market
continu gain share us refer laboratori updat refer laboratori
competit landscap vs vca regional/academ player
help us think strateg rational recent acquisit marshfield
lab vs org invest pipelin updat similar deal updat integr
think intern refer lab new sale forc effort ramp
refer lab strategi differ rel refer
laboratori strategi us current eu macro environ broader adopt
traction fecal antigen test refer lab
opportun improv refer laboratori profit thought recent dynam
vetconnect pet health network adopt stand
expect impact volum retent rate market share time
opportun better monet data asset
would character adopt trend digit radiographi capit equip
purchas trend vet clinic
think potenti telehealth/ virtual care opportun respons
social distanc protocol vet could trend impact
updat north america salesforc expans help us think ramp
new salesforc expect achiev optim product
direct distribut approach differ term cross-sel
promot activ bundl across refer lab in-hous
intern geographi target penetr
market today increment opportun better penetr across market
implic covetrus/vetsfirstchoic adopt work
updat relationship corpor account banfield
sustain market share posit growth higher margin segment
product launch new contamin outbreak would character
commit busi
character lpd demand trend ytd light covid impact would
character segment rel resili
speak key driver across livestock busi exposur lacklust
dairi end market residu african swine fever impact competit
think long term growth rate lpd busi see
increment opportun potenti invest bovin genom similar area
lpd segment predominantli intern lpd sale see
opportun domest commit lpd effort
thought ztss acquisit abaxi competit landscap evolv to-
date seen benefit disrupt market zts/abax
deal step taken maintain industri lead posit
may also move direct distribut model diagnost anticip
influenc purchas pattern rapid
given effort bundl therapeut diagnost offer custom
thought potenti partnership manufactur take similar bundl
approach shift sell strategi
abil work veterinari clinic well plan pet health insur util
geograph area focu particularli strong underli veterinari
character on-going dynam product anim demand current covid-
environ demand trend april may anticip
possibl recoveri normal trend trend differ domest
challeng dairi market see stabil pre-covid
give color underli demand view possibl long-term shift
demand trend
think demand trend across poultri swine dairi near term
next year give color speci impact
covid speci more/less vulner disrupt
updat process facil closur impact relev anim
busi segment insight reduc process
speak busi segment perform past recessionari
environ quickli typic see recoveri
past coupl quarter pivot dairi strategi gain market share
provid product larg scale cow dairi farm rather cater small
dairi farm give us color strategi progress
updat traction updat omnigen product
african swine fever impact china
think timelin possibl herd repopul china light
recent covid headwind
guid million headwind busi
essenti equat entireti china sale million still
sound right rang impact seen date seen
offset term increas demand america
see benefit larger amount us export pork china
zoeti point new commerci polici cattl brazil headwind
benefit
updat develop asf vaccin insight possibl
timelin comment usda potenti asf vaccin candid
talk foray companion anim provid color
expect busi remaind beyond
feel need scale readili compet companion anim
market compet use one-off product
talk in-licens companion anim technolog
platform complet product readi go-to-market
rejensa success far trial distribut period
color timelin top-lin impact product initi feedback
product mani veterinari clinic distribut product
updat lyme diseas project kind project could expect
broadli speak new product current develop key
area invest see meaning opportun certain therapeut
class speci
give color timelin invest strateg initi
think impact beyond spend frontend load
would character underli demand trend categori
headwinds/tailwind incorpor expect growth ex-
expect chang mix profit versu part
expect mitig effect antibiot regul potenti
regulatori environ becom challeng us intern
market mention product compar favor standard
greater opportun intern
give us updat osprey integr acquisit progress
osprey seem contribut slightli less expect million
color initi feedback possibl top-line contribut provia prime
speak traction omnigen europ china commentari
state us dairi competit dynam
view intern market pocket strength vs weak
outlook weak vaccin driven market
quantifi exposur viginiamycin
speak consumer-driven pressur busi
across miner nutrit busi clarifi impact sale gross
margin commod price increases/decreas
updat mecadox visibl fda request
traction poultri vaccin drove strong intern demand
divestitur perform product busi
updat aquacultur initi
provid color lt growth prospect vaccin nutrit specialti
expect double-digit growth segment resum longer term
character underli demand trend companion anim industri
speak drove custom growth give color
sticki covid-induc custom order pattern term
basket size mix compar prior quarter
much benefit stock dynam amidst dynam
view heighten on-line demand sustain near-term dynam
character order pattern current flea/tick season compar prior
season impact order pattern
note relationship major manufactur
implement map price expect relationship impact price
margin long term view manufactur open altern channel
character evolv competit landscap new concept
thought impact chewi on-line pharmaci on-line pet pharmaci
give color petm reward program impact custom retent
expect addit on-line marketplac entrant competit respons
exampl next gener product drove gross margin expans
signific consolid across space sever specialti brick
mortar competitor take omni-channel approach expect consolid
continu impact busi
think increment benefit gain next-gen parasiticid
flea/tick/heartworm combo benefit push sale vet channel
mobil app improv adopt trendsani impact revenu
gross margin compress driven addit discount off-set
competit market strategi go forward
custom acquisit cost declin significantli asid benefit heighten
on-line demand view hit inflect point custom
acquisit cost continu stabil declin
note advertis spend rise come quarter result season
relat flea/tick/heartworm season spend track compar
expect advertis strategi evolv less focus tv ad
success offlin advertis vs on-line updat custom acquisit cost term
offlin channel market hit former ad wont
much cut term sg
activ expect chang strategi
describ on-going demand shifts/opportun
brand gener
therapeut expect increas traction gener move forward
view role gener anim health
speak announc million invest on-line platform
improv aim drive million suffici expect increment
spend enhanc platform longer term updat timelin
would character current fundament dynam product anim
busi relat contraction/expans herd size feed cost cattl feed
relev variabl current pandem environ potenti
recessionari environ think speci segment next
coupl quarter beyond overal exposur
character impact meat process facil closur livestock
busi realist expect suppli chain capac recov
shift dine-in retail impact livestock busi
insight consum spend trend given current macroeconom environ
industri trend see current companion anim market
character vet util trend thu far april/may light pet ownership
trend spending/pet think timelin potenti recoveri
beyond
speak assumpt embed guidanc
oper top-line growth relat companion anim livestock
variou busi segment perform past recessionari environ
typic timelin recoveri
mention buy build strategi regard domest refer lab
elabor move sort timelin aim becom meaning
third parti player domest refer lab increas scale
remain independ domest refer lab quit small remain invest
primarili organ
speak strateg posit dognost bundl opportun
offer custom color initi feedback freedom flex offer
give color intern refer laboratori strategi
similar domest strategi potenti inorgan invest highlight
provid updat abaxi integr combin sale forc effort
bundl sap implement legaci abaxi perform us rel
expect market
livestock diagnost opportun envis timing/magnitud
potenti upgrad instal base abaxi instrument provid
updat chemistri analyz develop well pipelin opportun
acquir smb
initi feedback simparica trio launch domest market call
initi sale million distributor stock expect
stock dynam simparica cannib quarter
simparica trio compet thu far nexgard spectra europ
said expect million sale simparica trio vs prior
net exist parasiticid cannib covid impact launch
quantifi current size flea/tick/heartworm market opportun
expand market product like simparica trio cannib
updat pend monoclon antibodi pain felin canin
frame market opportun chronic felin pain critic unmet need
speak recent launch versican bb oral new canin oral vaccin
europ product differenti thought market opportunity/s
plan launch brand gener version elan rumensin next year
anticip compet huvepharma brand gener version
competit landscap draxxin anticip gener competitor near-term
thought norbrook new gener ceftiofur embed guidanc
anticip entrant
speak market opportun proheart cannib proheart
product help round parasiticid portfolio
speak market opportun revolut cat traction-to-d
apoquel opportun aggress price product quantifi
market potenti across acut vs chronic under-penetrated
veterinarian prescrib apoquel vs cytopoint level cannib
seen
thought competit landscap atop dermat view
competit threat kindr product much abl bundl
apoquel cytopoint help compet new entrant updat potenti
new entrant prepar term possibl life-cycle enhanc
top prioriti collabor regeneron mab
updat rimadyl competit landscap potenti offset sort
strategi take bundling/promot standpoint relat rimadyl
traction swine vaccin current market share
provid updat pharmaq underli fundament across aquacultur
opportun recent agreement pharmaq vinh hoan
vietnam size opportun alpha flux salmon parasiticid chile
potenti market product
altern antibiot product explor potenti non-antibiot anti-
infect peptid stand develop process
 dollar dedic novel therapeut vs life-cycle enhanc
speak covid dynam geographi tend see market
along term recoveri
geographi see largest opportun longer term companion
product anim altern area deemphas
exposure/impl african swine fever china see offset
protein sourc and/or geographi evid herd repopul
australia see market improv near term year drought
repres increment opportun market turn
vfd compar european regul well regulatori dynam
market expos product consumer-driven pressur
gross margin go longer term driver
speak margin flow-through impact color
profit implic ramp diagnost strategi simparica trio commerci
fx headwind color quarterli progression/ trajectori longer term
profit differenti livestock vs companion
annual price realiz longer term sustain
open establishing/ establish direct relationship e-commerc
platform chewi thought type direct distribut relationship
impact econom feedback vet channel
thought recent decis market product directli custom
independ third parti distribut plan deemphas
role third-parti distributor market effort
rational behind use distributor vs direct sale forc certain product
switch distribut vaccin parasiticid vs direct sale
continu abaxiss plan go direct exclus leverag
distributor dognost
pricing/exclus relationship larger veterinari chain distributor particularli
updat relationship corpor account
walk us two salesforc expans long take
new salesperson ramp follow expans rational expans
thought view broader implic newer concept
capit deploy opportun near term dividend hike de-lever
anticip share repurchas may resum billion author
expect broader industri consolid anim continu
expect competit landscap look like near term longer term kindr
chang landscap recent merger impact creat new
opportun challeng sale forc defect
work capit improv near term address high inventori day sap
implement influenc
give us updat underli demand trend amongst biopharma
could provid updat biotech fund environ healthy/on pace
balanc sheet covid-rel volatil
fundament demand differ across mid-siz biotech versu larg pharma
point differ significantli across differ earli stage function
discoveri safeti assess dsa
view trajectori discoveri long term outsourc penetr
bridg hsd organ growth rate guid lt aspir
pace progress far get better custom pull discoveri
 safeti assess goal current certain custom
type inclin
provid color busi mix citoxlab integr progress
kind custom overlap citoxlab synergi opportun
lap citoxlab acquisit stand margin expans
perspect put integr citoxlab relat previou
expect quickli think rais citoxlab oper profit margin
mid-teen pace de-lever par expect could
give us updat wil perform mpi
updat south san francisco cradl facil
longer term see addit opportun cell gene therapi
elabor strategi
speak strateg partnership bit revenu contribution/margin
profil see addit partnership opportun cell therapi
speak takeda partnership activ start acceler meaning
speak slippag experienc safeti assess resourc
delay contain china india notic bottleneck geographi
discoveri notic higher delay particularli across smid biotech
updat guidanc call rm organ revenu growth least
assumpt factor estim covid perspect assum
fulli recoveri
note rm impact covid break-out dynam
particularli research model busi
cost lever pull mitig nt covid headwind margin expect
rm supply-demand dynam look like recent research
model longer term expect perform
provid updat competit dynam within china competit
advantag leverag grow busi
emerg competitor china rm growth dynam
provid updat hemacar acquisit initi report
contribut million revenu grow next five year recent
call nt slowdown covid speak durat
headwind see addit opportun cell gene therapi supplement
speak manufactur support exposur covid disrupt
biolog could speak competit dynam long-term growth
opportun pa facil effect complet think ramp
util know microbi busi less capit capacity-intens
kind invest make area
volatil manufactur profit margin past quarter could
remind us lt expect segment margin profil
give us better sens cartridg pull endosaf product
quantifi volum unit price
seen abnorm buy patterns/hord could creat stock headwind
similar experi
impact covid vaccine/therapeut develop partnership
financi materi
covid vaccine/therapeut develop
particular therapeut area see particular strength
book other
describ natur hire initi expertis made
particularli strong hire much wage pressur see
speak vision real-tim studi data track capabl client
envis function work way see attract
near term prioriti target area interest asset
type opportun would find attract china standpoint
impact recent across larger pharma sponsor bmy/celg
implic recent envigo/cov transact benefit sort
speak expect broader recoveri clinic site step
take mitig inabl access investig site inaccess
effort increas remot virtual trial receiv sponsor
expect adopt virtual trial increas post-covid percent trial
transit remot
note outsiz covid-rel cancel expect trend
speak potenti opportun associ covid-rel chang order
extend enrol timelin discuss progress
updat cost mitig effort
experienc cash collect issu dynam see work
capit account see longer payment time custom and/or shorter
payment time investig
post net-btb comment mix new busi
win base term custom size geograph area therapeut expertis
speak underli demand trend across market term custom
provid updat predict pass-through make
headway better manag quarterli expect
speak acquisit symphoni clinic research
complement pmg research meddinova research updat site network
focu shift back larg pharma vs biotech speak
associ assumpt profit
expect backlog burn what drive chang
speak integr plan ahead schedul
updat site network strategi
 pipelin area focu network apac central lab expect bolt-on
strong balanc sheet consid larger transact
import leverag data improv win rate maintain data
strategi would ever think own data asset
speak recent trend across central laboratori busi estimate
revenu exposur covid
speak traction recent partnership announc practic fusion ag
trend see biotech fund environ base
convers smaller biotech custom
describ broader cancel environ particularli amongst larger
biopharma custom may expos vs smaller peer
discuss full servic vs vs hybrid model underli demand trend
favor one model custom prefer base compani size
much busi could quantifi size market
approxim rate grow faster/slow vs overal cro market
exposur pharma bmy/celg
expect non-pf growth beyond
recent extend prefer partnership two year scope
relationship chang financi implic
strateg allianc repres revenu see proport
chang negoti underway line sight new
speak recent medpass acquisit stand integr
expect revenu margin contribut
speak expect broader recoveri clinic site step
take mitig inabl access investig site inaccess
mention covid-rel cancel anticip
similar experi remaind
effort increas remot virtual trial receiv sponsor
expect adopt virtual trial increas post-covid percentag trial
abl convert remot virtual
speak potenti opportun associ covid-rel chang order
extend enrol timelin discuss progress
experienc cash collect issu dynam see work
capit account see longer payment time custom and/or shorter
payment time investig
updat cost mitig effort
would character rfp flow experienc strength similar
broad-bas across smid larg biopharma
elabor cross-sel effort integr solut group syneo
one reson marketplac updat increment million
book
surpris sinc inc research inventiv merger challeng
upsid surpris
confid long term hsd revenu growth target combin
entiti describ dynam segment get
experienc headwinds/tailwind relat pass through embed
speak profit margin progress long-term expect
previous target bp annual ebitda margin expans
next sever year bridg margin expans
acquisit kinaps expand offer provid
access differ type client differenti kinaps
sticki kinaps busi model clinic busi leverag
updat integr kinaps two quarter mileston sinc acquisit
stand term realiz synergi target
turnov sinc merger/cultur shift
target net leverag quarterli progress debt paydown
discuss dynam your see work capit account see
longer shorter payment time custom and/or longer/short payment time
hire progress see wage inflat
given chatter biopharmaceut space would
busi impact larg custom engag
expect cro consolid post-covid potenti opportun
growth area look invest move forward invest
speak cadenc million synergi expect
notic slowdown biotech fund compar
impli net btb provid color drove strength
across mix trial would breakdown recent new busi win term
size custom therapeut area fsp/full servic geographi
backlog burn declin sequenti speak underli dynam
complex clinic trial what realist rang backlog burn
speak larg strateg win experienc legaci commerci
custom partnership progress still expect drive revenu growth
speak price across industri everyon behav ration
enhanc clariti relat health industri
longer term growth rate differ segment within commerci advertis consult
outsourc penetr stand current basi commerci
think could go next year next year
defin quantifi backlog book metric
commerci net btb factor previous mention target
ttm net btb see pipelin evolv first half
year speak visibl
speak season see commerci segment
discuss underli growth rate across commerci busi
expect grow faster pace tradit cro market longer term
distinguish synh busi inventiv histor integr
commerci offer clinic offer
implic recent larg pharma bmy/celg
record covid-rel cancel speak natur
cancel expect cancel
site activ sinc end march seen sign
step take mitig inabl access investig site
effort increas remot virtual trial receiv sponsor
expect adopt virtual trial increas post-covid percentag trial
abl convert remot virtual
speak potenti opportun associ covid-rel chang order
extend enrol timelin discuss progress
experienc cash collect issu dynam see work
capit account see longer payment time custom and/or shorter
payment time investig updat cost mitig effort
updat us current rfp environ recent win rate
rfp environ chang outlook see acceler
rfi convert rfp think peer see environ given
differ custom mix
think model revenu basi given volatil
pass-through quarter-to-quart project-to-project basi btb
new target
would character current smid biopharma demand biotech fund
environ given exposur segment color recent custom pipelin
sort visibl intermediate/lt goal double-digit revenu
growth initi particular expect drive
potenti opportun larg pharma custom remain
focu ampl opportun smaller biotech leverag core compet
across nich
speak current price environ everyon behav ration
differ custom segment
previous mention rfp flow rfp qualiti two primari indic
measur broader cro health speak see current
environ materi chang sinc
differ book polici compar
impact book-to-bil backlog convers metric
speak natur new busi win latest quarter look
therapeut custom mix disproport larger contract
influenc new busi win
custom therapeut mix evolv next year
speak current custom concentr portion new award
come exist custom compar new custom
therapeut area focu particular categori see longer
studi start-up time complex therapeut area exposur exposur influenc
backlog convers trend seen industri constitu
discuss key differ exclus full-servic busi
model functional/piecem work full-
servic model impact growth potenti long-term margin profil
risk appetit moder think limit downsid busi
plan continu see strong book environ perhap
favor seen recent year
leverag data asset improv win rate speed start-up
competit landscap your compet new busi see
competitor tabl mayb unconvent player typic would see
specif regard larg tradit focu smid
lt target ebitda margin mind well covid think
quarterli progress profit speak increment
invest hire expect throughout year success gotten ahead
hire
current cra retent rate contribut better profit
trend locat cincinnati hurt help
opportun improv effici across central lab busi
recent reduc headcount adjust lower growth covid environ
expect return growth
term central lab busi provid updat see
demand perspect extent demand growth driven core full-
servic outsourc offer invest offer
previous mention stepped-up invest central lab busi
elabor initi think fit long-term return
histor acquisit net cash posit million
capit deploy strategi evolv could chang
think capit deploy prioriti elimin lt debt
see opportun small acquisit vertic would
like expand longer term
would ever seller obvious right price theori acquir
larger cro exclus full servic would impact busi
guid revenu million ebitda million
confid rang covid assumpt
make area conservat
guidanc assum clinic develop laboratori servic
revenu growth quickli expect busi recoveri post-covid
speak potenti offset relat headwind
award support vaccin treatment/cur clinic trial remind us
meaning financi impact would
step take mitig inabl access investig site
effort increas remot virtual trial receiv sponsor expect
adopt virtual trial increas post-covid
mention covid-rel cancel anticip
similar experi remaind
speak potenti opportun associ covid-rel chang order
extend enrol timelin discuss progress
experienc cash collect issu dynam see work
capit account see longer payment time custom and/or shorter
payment time investig
updat cost mitig effort
provid updat rfp environ recent win rate would
character growth across custom type larg pharma vs small- mid-siz
sort visibl intermediate/lt goal low-doubl digit
revenu growth excl covid initi particular expect drive
speak exposur complex therapeut area
expect exposur trend next twelv month longer term
updat current price environ everyon behav ration differ
custom segment
would character current demand trend across segment updat
think margin profil differenti clinic servic segment
rel laboratori solut expect margin profil two busi
trend time greater room expans non-covid
industri lead employe retent rate maintain high retent
also sustain industri averag oper margin
given chatter biopharmaceut space would
busi impact larg custom engag
growth area look invest move forward invest
uniqu rel rest cro industri consolid book
clinic laboratori servic togeth rational behind decis underli clinic
drove net btb expect book trend
expect backlog burn trend ntm lt extend
acceler burn rate laboratori book off-set inher slow clinic servic
record book as-award basi vs as-contract basi speak
broadli backlog polici help us think level conservat
embed book metric
composit backlog ta much backlog biotech pre-
meaning covid award mention call
addit project april/may
speak cross-sel effort across clinic servic laboratori
solut think potenti opportun associ
speak acceler enrol solut strategi role
extens site network vs proprietari dataset acurian drive differenti solut
tangibl data point demonstr success acceler patient recruit
walk us biotech offer differ rel
tradit model traction focus biotech model date win rate biotech
think exposur biotech custom today
expect custom mix go time
tradit cental lab would character growth rel market
market share total revenu
speak growth across analyt lab gmp bioanalyt biomark
vaccin busi perform to-dat
speak recent disclos collabor medabl scienc
capabl offer remot virtual trial offer
note covid-rel cancel expect
cancel
step take mitig inabl access investig site
effort increas remot virtual trial receiv sponsor
expect adopt virtual trial increas post-covid
speak potenti opportun associ covid-rel chang order
extend enrol timelin discuss progress
experienc cash collect issu dynam see work
capit account see longer payment time custom and/or shorter
payment time investig
updat cost mitig effort
provid commentari underli demand trend see
term book trend rfp volum also see chang broader
price environ competit landscap behav fairli ration moment
would character current demand trend across segment particularli
amidst updat overal exposur
give us detail behind differ underli demand trend
speak exposur complex therapeut area
expect trend come quarter also lt regard
start-up time elong expect continu
earli develop busi perform
speak long term growth prospect data solut busi
seen much way disrupt relat integr cro
recent unconvent space
account standard chang impact net servic revenu
recent quarter think model revenu basi
given volatil pass-through quarter-to-quart project-to-project
margin expect lt margin
backlog convers declin metric approach trough need
chang convers improv expect steadi state burn rate
takeda relationship roll accord intern plan
takeda novemb day announc plan spend billion
given strateg partnership much spend flow
share takeda increment spend concentr particular therapeut area
speak custom exposur takeda etc think
shake end year time
hire updat expect expens relat elev hire normal
speak current hire environ marketplac stand
term wage salari benefit recruit cost etc
speak implic custom consolid gener
histor impact busi
give detail behind breakdown full servic work
larger biopharma custom see shift industri demand trend
much think mix key factor help win new busi
think help gain share new strateg partnership win
provid color revenu concentr custom type vs larg
relat symphoni rational behind buy compani
previous simpli partner would character data asset competit
posit integr offer traction
platform lt growth rate
speak perform symphoni health rel expect sinc
acquisit complet mention confer call would
consid bolt-on help drive symphoni platform elabor type
busi meet criteria
speak januari acquisit innov integr
broader data strategi revenu contribut meaning
much data solut busi recur natur averag contract
provid color extent data invest driven custom
decis make favor observ market import
data offer custom make outsourc decis
speak natur invest make much
margin upsid could provid longer term
previous impli devis plan intern data asset
provid detail potenti method consid organ vs
rel healthi balanc sheet mind view current
speak opportun within govern agenc busi
expect invest begin gener revenu margin accret segment
therapeut focu govern contract target
note covid-rel cancel expect
cancel
step take mitig inabl access investig site
effort increas remot virtual trial receiv sponsor
expect adopt virtual trial increas post-covid
percentag trial abl convert remot virtual
view impact tradit approach clinic trial lt
speak potenti opportun associ covid-rel chang order
extend enrol timelin discuss progress
experienc cash collect issu dynam see work
capit account see longer payment time custom and/or shorter
payment time investig
quick recap speak key factor drove book
dynam recent quarter see book progress
speak mix new client win ytd larg vs smid biopharma
 busi perform well last quarter
take share level growth sustain
expect backlog burn trial complex
cro provid explicit guidanc give level
clariti inform perspect
note traction offer remain strong
million new busi quarter billion date discuss
combin data offer reson new exist custom
next gen book materi meaning top-line
speak abil manag expect around volatil pass-through
contribut post-asc world
detail natur new larg pharma partnership ink combin
ta continu perform well key driver percentag ta
recur oce meaning driver speak broader opportun take
share market relationship roch
mention larg pharma renew cycl provid opportun drive
greater uptak oce offer next month speak
strategi drive adopt would character convers
previous estim oce billion estim hold today
rate market grow competit advantag provid color
revenu margin profil contract
speak overal price environ competit
remind us medium term goal term growth rate across core
busi expect growth ramp
fund environ close tie broader biotech fund
environ see term broader demand trend
could provid updat effort continu grow faster
pace tradit full-servic demand trend sale
percent incom rfp leverag gen/cor combin offer
today percent expect next year percent rfp
appli fix price model
expect see book strength convert meaning revenu
growth acceler revenu come quarter
speak margin trend segment think profit
cadenc time invest drive higher margin
go forward oce effect margin
give updat traction emerg biopharma
provid updat cost save target accomplish
merger-to-d ahead plan behind plan term cost synergi
run surpris front sinc close merger
combin busi help bolster world evid offer
growth rate rwe color new real-world prefer partnership
stand term virtual trial concept associ initi
place
term prioriti continu tuck-in deal target
area current healthi deal pipelin continu expect deal add
percentag point growth annual estim deal spend
hole fill technolog offer commerci solut busi
describ recent acquisit made relat
platform updat de-lever share repurchas activ
provid color hire initi wage inflat
see hesit across custom base concern around drug price
speak jv quest recent announc genom test lab
build-out well overal central lab industri perform
lead presidenti elect cycl expect chang pharma/biotech
decis make notabl trend impact elect
speak drove organ growth despit covid impact late
quarter would growth look like normal environ
pars put take net benefit gain
covid dynam quarter expect benefit continu
chanc stocking-rel benefit go away lead downsid
help us understand -lsd growth call april end market
addit color whether see edu government lab ramp back
particularli lab involv covid research
expect hsd growth biopharma continu environ
healthcar big headwind postpon elect procedur
could see tailwind come back on-line
put take adv appli materi consid uniqu
exposur market like petrochem gold
speak driver sustain robust cash flow
past coupl quarter spoken sever new custom contract win
vwr/avantor merger enhanc posit marketplac
note earn call youv captur target million
run-rat synergi thu far expect increment synergi captur
vwr integr continu drive margin expans time
sort margin expans expect see annual much margin
expans driven oper leverag vs price strategi vs mix
help us think oper margin profil proprietari product rel
third parti product sell channel margin profil servic
high mix recur revenu revenu rel life
scienc tool diagnost peer expect mix chang time
speak exposur key growth area biopharma market
think potenti impact biopharma custom
consolid previou transact impact contract profit profil
also discuss potenti implic consolid supplier side
thought pend ge biopharma transact
potenti near long-term opportun new protein chromatographi resin
go-to-market strategi initi custom recept
speak leadership chang america drove shift
process find perman replac leader region vs ceo
michael stubblefield act head america interim basi
key driver biopharma america compar
histor experi region would drive growth acceler
pars educ govern experi america
think end-market
congress recent pass budget includ increas nih fund
compar intern expect help us think impact
thought head elect cycl
healthcar slightli help us understand your see
market pocket strength weak expect remaind year
put take perform europ quarter
key driver behind strength organ growth
speak biopharma perform europ hsd underli
driver expect biopharma continu grow rang lt
unpack perform date educ govern end-
market europ well expect market covid restrict
loosen see fund standpoint thought horizon europ
think lsd growth across healthcar driver
growth sustain could return higher level beyond
pars industri experi impact on-going oil crisi overal
meaning contribut industri overal geograph segment
speak key driver growth area weak
announc separ amea region two commerci sub-seg
new evp sven henrichwark respons grow presenc apac driver
strategi shift thought henrichwark prior experi vs current strategi
speak dynam amea quarter impact suppli
disrupt india see resolut disrupt
long-term expect apac exposur sale
speak invest make five key hub india
korea/japan south east asia china east/africa amea progress
potenti run ahead/behind plan relat market
youv note meaning invest biopharma region larg
biopharma busi amea vs end market skew driven
particular market updat underli biopharma environ amea
exposur end-market healthcar educ govern
appli technolog aerospace/defens amea speak underli
environ end-market relat amea region
help us think capit deploy prioriti think
share repurchas vs debt pay vs
would consid implement dividend near longer term would
impetu initi dividend
term speak see pipelin type
deal interest ad capabl geograph expans size
deal current look remind us target leverag rang
highest level leverag comfort oper
conjunct ep report announc rainer blair current evp
life scienc succeed tom joyc ceo septemb rational
begin transit midst
provid guidanc core revenu growth ex cytiva ge
biopharma fairli broad rang speak underli assumpt
drive perform high end guidanc end
segment think core revenu growth across life scienc
diagnost underli growth driver
give us breakdown perform geographi speak
perform trend cours april improv across certain
give us updat integr ge biopharma deal
target timelin chang light pandem
compar integr ge pall similarities/differ synergi
speak mix/focu shift post-ftv spin inher
healthcare-focus recur revenu stream newer/young product line
lt margin expans target detail db oper effici
initi progress longer term nt
lt margin leverag stem
e-commerc appli busi competit
threat opportun view
global effort strategi take hold high growth market area
expect focu longer term growth area posit
speak polit chang dc view biggest factor
could influenc busi whether healthcar reform pama tax trade
geographic-specif regulatori develop pay attent recent
think impact life scienc segment
extent increment research relat support growth pharma
biotech custom work antivir therapi vaccin immun respons research
convers note youv experienc headwind across life scienc
platform closur academ research lab remind us exposur
research lab expect academ research lab begin open
meaning expect pace recoveri look like
speak underli growth driver expect whether level
growth continu particularli light covid dynam
break expect ge biopharma growth rate product line single-us
outlin key fundament driver bioprocess single-us evolut etc
influenc life scienc segment meaning next year
youv note nih fund directli impact busi
exposur current demand trend fund metric correl busi
lt growth rate across beckman life scienc sciex leica microsystem
pall particularli strong nearli greater hsd core growth
speak underli driver lt growth rate busi
integr timelin kind ramp expect plan
expand intern outlin synergi opportun
speak product innov beckman life scienc life scienc
give us updat underli end market trend across diagnost
think impact busi near-term
diagnost experienc sustain strength call driver
strength whether expect continu
specif cepheid experienc core growth speak cepheid
perform rel expect region extent molecular
test contribut result
think cepheid longer term potenti growth run-rat
beckman coulter expect busi receiv emerg use
author us fda antibodi test near term current
embed guidanc fast ramp product demand level help
us think potenti financi opportun serolog test
margin expans opportun diagnost
speak impact across segment mention
consum still fairli solid albeit equip purchas delay
remind us busi mix driver
updat industri fundament best measur busi
think long term growth rate growth profil segment hach
lt driver view idexx busi regulatori
polit environ municipal/ govern project demand trend
secur ge biopharma financ significantli lower cost
anticip allow delev quickli affect near-term
approach would open potenti larger deal sooner previous
water pid posit sustain growth without firepow delev
plan cadenc debt paydown
tariff impact think attract variou market
recent provid guidanc call flat core revenu growth
help us better understand releas wide guid drive
perform top end rang bottom end rang
area busi vulner dynam resili
last year rais organ revenu growth long term target vs prior
still remain confid acceler sustain longer term
speak organ growth algorithm normal environ extent
growth driven price vs volum vs innovation/new product launch given year
margin perspect analyst day note expect roughli
bp margin expans annual drive oper margin
still confid longer term outlook remind us primari driver
margin expans next year
high mix recur revenu revenu rel life scienc tool
 diagnost peer expect mix chang time
speak exposur key growth area biopharma market
one industri lead budget annual alloc
resourc intern across segment product group key area focu
term intern invest
bioproduct market remain key growth area speak
current posit may evolv given certain activ across market
exposur fast-grow dd bioproduct busi
expect go time
across bioproduct landscap speak posit across single-us
technolog cell cultur media market grow market
segment rel competitor
fisher channel busi perform chang competit
relat channel busi think potenti impact
biopharma custom consolid previou transact
impact contract profit profil previous
extent channel sale gener on-line platform websit
provid updat integr brammer think
busi growth profil longer term
capac util current stand across platform
expect trend next year next three year
thought profit expans opportun across lp particularli util
ramp lp oper profit margin go longer term
attribut weak across analyt instrument outsiz exposur china
sale begin slow china rational
hear around slowdown cancel deferr
seen recov across busi china
provid updat fei cryo-em perform cours
well outlook backlog current stand
speak posit chromatographi mass spectrometri market
rel competit offer busi grow rel
updat molecular test covid believ suffici capac
million test week meet demand expect increas capac
help us understand lab hospit would choos qpcr test
given recommend defer elect treatment test extend core
test declin last two week march see far
thought serolog test relat covid view
next best step get pandem control effort focus elsewher
elabor commerci contract renew pct test busi
creat short term headwind million revenu expect
renew support posit time durat contract
launch cascadian analyz remind us potenti
market opportun product enhanc posit market
cascadion ramp meaning contribut
think instrument
help us think capit deploy prioriti think
share repurchas vs dividend vs debt pay vs
lead consolid highli fragment market signific
compon growth stori histor speak strategi
youv abl enhanc positioning/stori time key factor
consid look acquisit
term speak see pipelin type
deal interest current ad capabl geograph expans end-
market size deal current look
speak strateg rational recent announc qiagen
deal qiagen fit longer term growth stori
also provid updat deal progress note
call still expect deal close risk
regulatori review delay due covid data point
youv quit activ space acquisit patheon
brammer well facil expansions/acquisit throughout
expect across market enhanc
labcorp america lh
give us updat underli fundament util trend across core
clinic lab busi expect organ volum growth trend
volum note core volum end march
seemingli stabil mid late may see current
seen rebound driver
covid help us think potenti benefit experi
increment molecular serolog test relat extent
off-set pressur across core volum
covid pcr test updat current molecular test capac
covid serolog test detail new serolog antibodi test capac
today go time driver capac expans new
manufactur test market thought potenti reimburs market
manag contract extent expect continu volum
headwind relat horizon bcb contract shift
prefer lab network sort impact anticip unh
new prefer lab network announc longer term
expect manag care provid implement pln next
year expect util wait see type polici
term beacon lb pilot non-renew florida spoke
bp impact revenu per requisit associ volum
impact broadli help us understand impact across
surpris drove bp volum headwind
particularli follow weak throughout think
underli dynam busi current exposur go forward expect
calendar day dynam competit landscap profit dynam
think contributor volum growth go forward
updat bcb florida contract potenti win dgx/open non-
updat acla pama lawsuit
thought pama relief care act longer term implic
comment chang see hospit insourc outsourc
trend would character current pipelin
market share vs rest market trend time
view longer term normal trajectori next year
give us updat walgreen relationship store
store lt see volum consist patient servic center test mix
speak potenti implic covanc unit
see term studi start access site extent trial
convert start virtual trial
post ttm btb recent quarter despit covid dynam
potenti delay studi start help us understand underli dynam
character current book trend
see abnorm level cancel cancel relat lack fund
mention youv win fair share clinic trial relat
vaccin therapeut help us think benefit
could potenti experi financi materi
speak seen recent term biotech fund rfp
well expect
initi place acceler voluntari opt-in clinic trial databas
new busi award relat combin services/data offer
speak strateg rational envigo acquisit includ
purchas envigo preclin research servic busi sale covanc
research product busi alreadi embed guidanc term
contribut transact
investor question commit preclin busi prior envigo
deal vision busi segment longer term improv
overal posit covanc
youv mention trial leverag combin data asset across
covanc labcorp busi speak custom feedback
offer provid metric help us think support drug
develop process client
opportun better leverag patient servic center build walgreen
relationship virtual trial concept
your divers custom mix limit exposur speak implic
broader pharma industri consolid
provid updat launchpad initi potenti acceler
even increas cost save
expect covanc adj ebit margin reach lt
compar preclin clinic competitor
speak launchpad phase ii focus lcd segment
think potenti cost cut opportun
 pipelin see acceler discuss relat pressur
industri pama/mco contract shift
weve posit clinic laboratori inform technolog play
commod servic provid appropri rel busi mix/futur
monet vast amount data collect cours
oper lab busi area data could provid
use synergi outsid cro space
view offer light data-driven offer
marketplac
volum price dynam
think put take organ volum growth
remaind light forese bolu core
test demand social distanc protocol eas recoveri
longer term visibl core test volum look like
give us updat current molecular test capac test
perform date turnaround time
speak differ molecular test volum geographi
give detail new serolog antibodi test
volum capac expect think big pictur high could volum
go test color reimburs level
extent covid test mitig core volum declin
postpon elect procedur materi headwind much
volum could recov procedur start come back
histor rel low medicaid exposur sort mix shift
associ margin impact expect consid current econom environ
give color current telemedicin relationship strategi
front telemedicin gain promin respons social distanc protocol
provid updat contract shift
perform across cohort rel intern expect much share
anticip captur unh/horizon perform
aetna consid labcorp in-network provid
think potenti opportun relat part unitedhealth
prefer clinic laboratori network overal intent pln
think impact longer term
expect payor adopt prefer lab network go forward
wait see dynam larger-scal adopt could broader use
prefer network mean broader lab industri
unh prefer lab network differ previous util
criteria consid pick prefer lab provid
speak incentiv patient physician util pln member
potenti method payor util market deliv patient lower
cost provid like
see increment pressur commerci insur use clf price
refer point much contract essenti lock next
youv mention insur live consid in-network vs last
year would character constitu cohort
sizabl residu exclus competitor
provid updat pama relief effort progress
thought recent passag care act impact
longer term impact legisl action view
insight next round stimulu packag
implic medicar sequestr suspend may-decemb
view gain goodwil regul amidst current
environ may help futur polici negoti
follow coupl year pama exposur medicar today
percentag volume/revenu medicaid
begin late experienc meaning step patient
concess patient concess trend recent initi
intern manag dynam go forward year-over-year dynam
consid patient concess standpoint
stand safeway partnership mani store
current partner evolv next year
expect expans safeway comfort current
relationship see volum loss transit consolid associ psc
made progress addit basic healthcar servic youv talk
provid locat provid color point
possibl would partner addit compani part retail initi
limit safeway forese futur
speak quest direct offer help us understand better posit
market earli adopt progress custom feedback
updat site care initi innov
mention call may risk breach debt threshold
net debt/ttm ebitda soon stand term financi
coven point time negoti lend facil proceed
updat regard durat impact temporari cost save initi
put place mitig headwind
guid cost save year invigor program
initi progress rel expect captur thu far help us
understand cost save realiz across cog vs sg
relat potenti monet data work other
cros/pharma updat signific opportun well-
posit market vs competitor vs labcorp in-hous cro
 pipelin see import opportun pursu
mention deal convers timelin elong due complex
scope size deal drive convict abl continu achiev
contribut longer term
announc new profession lab servic pl agreement cathol
servic long island juli memori hermann texa jan
remind us pl strategi support overal growth strategi
posit market pipelin look like type deal
see increas pace deal progress increas potenti deal
given pama primarili hospit outreach lab space see
independ lab well
speak expand initi across advanc diagnost market
anticip dilut effort
think size advanc diagnost market opportun market
growth rate vs
blueprint genet speak rational acquisit better
posit market revenu contribut profit dynam
liquid biopsi invest rational exactli flow
speak demand rt-pcr covid test price differenti
mention potenti ramp covid test capac tests/day
test/day end current demand trend justifi expans
at-hom covid test kit approv still expect price
longer term expect covid test catalyz new custom relationship
speak broadli test volum progress test volum ta
withdraw guidanc call asp light
covid think
note core test volum sinc core volum
progress expect normal
covid test impact asp increment volum off-set core test declin
speak recent reimburs propos hereditari cancer screen
anticip headwind reimburs pressur
speak sequenc servic offer weigh asp
speak underli demand trend across market particular
major new partnership pipelin awar
busi progress sinc licensur new york
sign new suppli relationship provid covid test
competit process see opportun expand relationship
provid color new relationship establish
recent parkinson foundat juli columbia januari stemcyt
price trend see current see pressur particular
segment competit environ anticip price degrad
come quarter
lt gross margin target break asp cost per test dynam
big salesforc anticip chang
 pipelin look speak area invest includ
probe bioinformat test offer
market product categori /or custom plan target next
genet test still earli stage adopt challeng face
compar result other
barrier reimburs competitor struggl
expand third-parti payor predominantli cash impact
approach reimburs differ peer
help us understand detail intern initi
opportun near term revenu potenti
commerci payor sign date
aspect technolog believ difficult replic cant
other thing
discuss regulatori environ affect go forward
light declin see floor
mention proactiv outsourc servic provid
speak scenario play
reveal interest pursu elabor specif industri
interest think balanc organ growth bolt
walk us key growth driver throughout rest year would
character fundament demand trend outlook progress
current environ
main driver revenu declin call late
march/ earli april expect declin mark trough impact
pandem
give color impact postpon elect procedur
demand defin progress echocardiogram volum
past weeks/month compar prior year insight timelin recoveri
normal demand
note ntp suppli issu larg allevi
think roll-off suppli challeng confid suppli level
long-term issu resolv speak impact covid-
relat travel restrict suppli
speak competit landscap ultrasound contrast market defin
opportun extend product life-cycle
call said gross margin would compress compar level
give color margin flow-through revenu declin updat
impact new manufactur facil margin
speak defin initi europ new partnership bring
defin italy/portugal/spain achiev meaning traction intern
give us updat potenti meaning chang reimburs
environ across core product line
defin rt next step defin rt complet
qualif batch remind us relationship samsung
elabor competit landscap room temperatur contrast agent
lvef go benefit trial result whether plan pursu
indic result effect long-term outlook
market opportun defin
lmi fda grant orphan drug design use lmi
neuroendocrin tumor august note possibl elig rare pediatr
diseas prioriti give us updat pipelin prioriti
approv
flurpiridaz speak next develop catalyst trial enrol
quantifi market opportun
china market entri updat packaging/tri delay doubl crane
see opportun
manufactur speak on-going manufactur invest give
color implic genesi project come on-line profit implic
intern contrast ultrasound societi petit fda remov black
ultrasound contrast agent label impact demand/util trend
updat defin ip specif pertain patent expir come year
speak competit landscap molybdenum
speak ansto new facil think help
sourc suppli time
make bwxt announc abl bring technetium-
product market competit posit
speak new xenon competit entrant differ competit
entrant past relev geographi
discuss contract strategi nuclear product technelite/xenon
contract volum versu prior year current covid
environ impact volum
think cerevast relationship applic beyond ocular
relationship carterra opportun microbubbl use oncolog
elabor margin differenti defin technelite/
investor still understand regard deal recent feedback
gotten seen feedback evolv
updat relationship velan capit come support
deal
go detail strateg rational amend deal term
give us background phase condor trial read-through much
confid give pyl asset achiev target outlin
amend term million million
updat repriorit pipelin consid addit progen
updat progen pipelin
give color breakdown revenu specif asset
mention million azedra pyl project
breakdown ramp like azedra assumpt
evolv follow result phase condor trial
expect timelin
give us color expect impact gross margin initi
time call azedra higher margin compani averag
forecast impli realli meaning gross margin ramp
underli assumpt
tent breakdown sg cost decreas
percentag revenu time asset leav pipelin head
delay sharehold vote june impact
assumpt relat contribut potenti synergi captur
compani mention price
labcorp america lh
